{"id":5569,"date":"2025-07-24T23:02:27","date_gmt":"2025-07-24T23:02:27","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/07\/24\/readout-loud-podcast-sarepta-gene-therapy-duchenne-narcolepsy-cancer\/"},"modified":"2025-07-24T23:02:27","modified_gmt":"2025-07-24T23:02:27","slug":"readout-loud-podcast-sarepta-gene-therapy-duchenne-narcolepsy-cancer","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/07\/24\/readout-loud-podcast-sarepta-gene-therapy-duchenne-narcolepsy-cancer\/","title":{"rendered":"A mother\u2019s perspective on Sarepta\u2019s gene therapy halt"},"content":{"rendered":"<p>    A mother\u2019s perspective on Sarepta\u2019s gene therapy halt<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>How are families of patients reacting to the removal of Sarepta\u2019s gene therapy from the market?  Why are investors excited about narcolpesy drugs? And why has there been less financing in oncology startups?<\/p>\n<p>We chat about all that and more on this on this week\u2019s episode of \u201cThe Readout LOUD,\u201d STAT\u2019s biotech podcast. We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta\u2019s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/07\/24\/readout-loud-podcast-sarepta-gene-therapy-duchenne-narcolepsy-cancer\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein, Elaine Chen, and Allison DeAngelis<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/07\/24\/readout-loud-podcast-sarepta-gene-therapy-duchenne-narcolepsy-cancer\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A mother\u2019s perspective on Sarepta\u2019s gene therapy halt How are families of patients reacting to the removal of Sarepta\u2019s gene therapy from the market? Why are investors excited about narcolpesy drugs? And why has there been less financing in oncology startups? We chat about all that and more on this on this week\u2019s episode of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2154,2159,2208,2659,2155,2265],"tags":[2150],"class_list":["post-5569","post","type-post","status-publish","format-standard","hentry","category-biotechnology","category-cancer","category-drug-development","category-gene-therapy","category-pharmaceuticals","category-the-readout-loud","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5569"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=5569"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5569\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=5569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=5569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=5569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}